Drotrecogin alfa (activated): real-life use and outcomes for the UK

doi:10.1186/cc6879

Critical Care

Volume 12
Issue 2

Viewing options:

Abstract
Full text
PDF (348KB)
Additional files

Associated material:

PubMed record

Related literature:

Articles citing this article
on BioMed Central
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Rowan KM
Welch CA
North E
Harrison DA

on PubMed

Rowan KM
Welch CA
North E
Harrison DA
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Research

Drotrecogin alfa (activated): real-life use and outcomes for the UK

Kathryn M Rowan , Catherine A Welch , Emma North and David A Harrison

Intensive Care National Audit & Research Centre, Tavistock House, Tavistock Square, London WC1H 9HR, UK

author email corresponding author email

Critical Care 2008, 12:R58doi:10.1186/cc6879


Published:	22 April 2008

Additional files

Additional file 1:

Data collection form completed for admissions that received DrotAA. Presented is the data collection form completed for patient admitted who received DrotAA.

Format: PDF Size: 74KB Download file

This file can be viewed with: Adobe Acrobat Reader

Additional file 2:

Timeline of the audit of DrotAA and other key events. Shown is the timeline of the audit of DrotAA and other key events.

Format: PDF Size: 39KB Download file

This file can be viewed with: Adobe Acrobat Reader

Additional file 3:

Balance between admissions receiving DrotAA and matched controls. Shown is the balance between patients admitted who received DrotAA and matched control patients.

Format: PDF Size: 15KB Download file

This file can be viewed with: Adobe Acrobat Reader

Additional file 4:

Propensity model for use of DrotAA. Shown is the propensity model for use of DrotAA.

Format: PDF Size: 21KB Download file

This file can be viewed with: Adobe Acrobat Reader